K A Breen1, K Sanchez2, N Kirkman2, P T Seed3, K Parmar4, G W Moore2, B J Hunt5. 1. Guys and St.Thomas' NHS Foundation Trust, London, United Kingdom. Electronic address: karen.breen@gstt.nhs.uk. 2. Viapath, Guys and St.Thomas' NHS Foundation Trust, London, United Kingdom. 3. King's College, London, United Kingdom. 4. Guys and St.Thomas' NHS Foundation Trust, London, United Kingdom. 5. Guys and St.Thomas' NHS Foundation Trust, London, United Kingdom; King's College, London, United Kingdom.
Abstract
BACKGROUND: The antiphospholipid syndrome (APS) is the association of thrombosis and recurrent pregnancy loss and/or pregnancy morbidity with persistent antiphospholipid antibodies (aPL). Previous studies of microparticles in patients with APS/aPL have mainly been small and findings, contradictory. OBJECTIVES: To quantify endothelial and platelet microparticle levels in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome (PAPS). PATIENTS/ METHODS: We measured endothelial and platelet microparticle levels by flow cytometry in 66 aPL/PAPS patients and 18 healthy controls. RESULTS: Levels of circulating platelet (CD41 and CD61) and endothelial microparticles (CD51 and CD105) were significantly increased in patients with PAPS and aPL compared to healthy controls. There were correlations between platelet and endothelial microparticles levels in all patients with aPL. CONCLUSIONS: Platelet and endothelial microparticles are increased in all patient groups within this cohort of patients aPL. Whether they may have a role in the pathogenesis of APS merits further study.
BACKGROUND: The antiphospholipid syndrome (APS) is the association of thrombosis and recurrent pregnancy loss and/or pregnancy morbidity with persistent antiphospholipid antibodies (aPL). Previous studies of microparticles in patients with APS/aPL have mainly been small and findings, contradictory. OBJECTIVES: To quantify endothelial and platelet microparticle levels in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome (PAPS). PATIENTS/ METHODS: We measured endothelial and platelet microparticle levels by flow cytometry in 66 aPL/PAPS patients and 18 healthy controls. RESULTS: Levels of circulating platelet (CD41 and CD61) and endothelial microparticles (CD51 and CD105) were significantly increased in patients with PAPS and aPL compared to healthy controls. There were correlations between platelet and endothelial microparticles levels in all patients with aPL. CONCLUSIONS: Platelet and endothelial microparticles are increased in all patient groups within this cohort of patients aPL. Whether they may have a role in the pathogenesis of APS merits further study.
Authors: Sarah N Lauder; Keith Allen-Redpath; David A Slatter; Maceler Aldrovandi; Anne O'Connor; Daniel Farewell; Charles L Percy; Jessica E Molhoek; Sirpa Rannikko; Victoria J Tyrrell; Salvatore Ferla; Ginger L Milne; Alastair W Poole; Christopher P Thomas; Samya Obaji; Philip R Taylor; Simon A Jones; Phillip G de Groot; Rolf T Urbanus; Sohvi Hörkkö; Stefan Uderhardt; Jochen Ackermann; P Vince Jenkins; Andrea Brancale; Gerhard Krönke; Peter W Collins; Valerie B O'Donnell Journal: Sci Signal Date: 2017-11-28 Impact factor: 8.192
Authors: Andreas Funke; Adriana Danowski; Danieli Castro Oliveira de Andrade; Jozelia Rêgo; Roger Abramino Levy Journal: J Vasc Bras Date: 2017 Apr-Jun